in vivo data before tweaking in vitro [Dissolution / BCS / IVIVC]

posted by Kiran – 2017-06-24 22:19 (2936 d 08:17 ago) – Posting: # 17502
Views: 8,564

Hello Mr.Helmut,

Firstly very thankful for your quick response.

Your input is valid but the thing is the dissolution method in which my generic product is faster is given in the FDA guidance and I am bound to meet f2 value w.r.t to that of the reference product.

One more thing is that the drug shows local action in the gut so invitro profile is more relevant to show comparison with that of the reference product.

The main reason I am presuming is the variation in the solubility of drugs in reference and test product to be the major reason for the variation in the dissolution profile due to polymorphic difference.The drug in the reference product has low solubility.

Regards,
Kiran.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,695 registered users;
61 visitors (0 registered, 61 guests [including 21 identified bots]).
Forum time: 06:37 CEST (Europe/Vienna)

If I’d observed all the rules,
I’d never have got anywhere.    Marilyn Monroe

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5